Breast Cancer: Alliance A011502 (ABC Study)

A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: The ABC Trial

Objective

The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer.

Some studies have suggested that aspirin may lower the risk of breast cancer coming back, but others have not, so we do not know if aspirin will help decrease breast cancer recurrence. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo. Aspirin is approved by the Food and Drug Administration (FDA) of the United States, but is not approved for the purpose of lowering the risk of breast cancer coming back or improving survival.

For more information please visit the National Cancer Institute.

LOCATIONS:

1.  Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number:  563-421-1900

2.  Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3.  Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number:  563-345-4325

Clinical Trial Categories

  • Breast Cancer
Sponsor(s)
Alliance for Clinical Trials in Oncology
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email